SAN DIEGO, Oct. 21, 2021 (GLOBE NEWSWIRE) --

Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal securities laws by Novavax, Inc. ("Novavax" or "the Company") (NASDAQ: NVAX).

On October 19, 2021, Politico published an article titled “They rushed the process’: Vaccine maker’s woes hamper global inoculation campaign” which stated, “The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.”

Following this news, Novavax stock closed down 14.76% on October 20, 2021.

If you have information that could assist in this investigation, including past employees and others, or a Novavax shareholder and are interested in learning more about the investigation, please contact Jim Baker (jimb@johnsonfistel.com) by email or phone at 619-814-4471. If emailing, please include a phone number.

Additionally, you can [click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com

[click here to join this action]